Recent

% | $
Quotes you view appear here for quick access.

XOMA Corporation Message Board

  • mdwhittier mdwhittier Oct 31, 2013 10:55 AM Flag

    Short Data Set

    The market was looking for something wildly positive in the EOA data, which was only 3 months of treatment. Since Gevo is only dispensed 1x a month, it makes sense that a full 6 months of data would give a much more complete picture of efficacy. Safety does not appear to be an issue, so that's a real positive. There's a lot to like about Gevo, but at this point it's a drug looking for a market, or markets. It will eventually succeed, IMO, but additional clinical trials will be needed to determine the best application for the drug.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
XOMA
0.81-0.07(-7.95%)2:11 PMEDT